(EQNR) Equinor ASA - Overview
Stock: Crude Oil, Natural Gas, Wind Power, Hydrogen
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 7.38% |
| Yield on Cost 5y | 16.14% |
| Yield CAGR 5y | 31.12% |
| Payout Consistency | 90.2% |
| Payout Ratio | 50.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.0% |
| Relative Tail Risk | 0.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.83 |
| Alpha | 16.72 |
| Character TTM | |
|---|---|
| Beta | 0.480 |
| Beta Downside | 0.890 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.70% |
| CAGR/Max DD | 0.08 |
Description: EQNR Equinor ASA January 27, 2026
Equinor ASA (NYSE:EQNR) is a Norwegian-based integrated energy group that spans the full value chain-from upstream exploration and production in Norway, the rest of Europe, and the United States, to midstream transport, refining, marketing, and emerging renewables such as offshore wind, green hydrogen, and solar. The firm also pursues carbon-capture-and-storage (CCS) projects and diversified logistics (pipelines, shipping, trucking, rail). Formerly Statoil, it rebranded to Equinor in 2018 and has operated since 1972 from its headquarters in Stavanger.
Key recent metrics (as of Q4 2025):
• Adjusted EBITDA reached **$12.3 billion**, reflecting a 9 % YoY rise driven by higher realized oil prices (average $84 / boe) and tighter operating margins.
• Upstream production averaged **2.2 million boe/d**, with a 4 % increase in Norway’s offshore output and modest growth in the U.S. Eagle Ford basin.
• Capital expenditure for 2024 was **$14 billion**, of which roughly **$3.2 billion** was allocated to renewable and CCS initiatives, including the Northern Lights CCS hub (targeting 1.5 Mt CO₂/yr) and a 2.5 GW offshore-wind pipeline slated for commissioning by 2028.
These figures sit against sector-wide drivers such as OPEC+ production policy, volatile crude benchmarks, and accelerating ESG mandates that are reshaping investment flows toward low-carbon assets.
For a data-rich, quantitative deep-dive on Equinor’s valuation dynamics, check the latest analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 5.73b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.68 > 1.0 |
| NWC/Revenue: 7.22% < 20% (prev 15.90%; Δ -8.68% < -1%) |
| CFO/TA 0.15 > 3% & CFO 20.36b > Net Income 5.73b |
| Net Debt (22.84b) to EBITDA (40.34b): 0.57 < 3 |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.63b) vs 12m ago -4.99% < -2% |
| Gross Margin: 37.59% > 18% (prev 0.42%; Δ 3717 % > 0.5%) |
| Asset Turnover: 79.03% > 50% (prev 77.57%; Δ 1.46% > 0%) |
| Interest Coverage Ratio: 19.70 > 6 (EBITDA TTM 40.34b / Interest Expense TTM 1.44b) |
Altman Z'' 3.38
| A: 0.06 (Total Current Assets 41.45b - Total Current Liabilities 33.72b) / Total Assets 135.85b |
| B: 0.35 (Retained Earnings 47.94b / Total Assets 135.85b) |
| C: 0.21 (EBIT TTM 28.42b / Avg Total Assets 135.48b) |
| D: 0.43 (Book Value of Equity 40.52b / Total Liabilities 95.25b) |
| Altman-Z'' Score: 3.38 = A |
Beneish M -2.99
| DSRI: 0.71 (Receivables 10.37b/14.21b, Revenue 107.07b/104.81b) |
| GMI: 1.12 (GM 37.59% / 41.98%) |
| AQI: 1.44 (AQ_t 0.25 / AQ_t-1 0.18) |
| SGI: 1.02 (Revenue 107.07b / 104.81b) |
| TATA: -0.11 (NI 5.73b - CFO 20.36b) / TA 135.85b) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of EQNR shares?
Over the past week, the price has changed by +2.50%, over one month by +18.77%, over three months by +16.24% and over the past year by +28.49%.
Is EQNR a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EQNR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.2 | -12% |
| Analysts Target Price | 24.2 | -12% |
| ValueRay Target Price | 31 | 12.7% |
EQNR Fundamental Data Overview February 07, 2026
P/E Forward = 10.1729
P/S = 0.6205
P/B = 1.6545
P/EG = 3.5734
Revenue TTM = 107.07b USD
EBIT TTM = 28.42b USD
EBITDA TTM = 40.34b USD
Long Term Debt = 22.90b USD (from longTermDebt, last quarter)
Short Term Debt = 5.88b USD (from shortTermDebt, last quarter)
Debt = 30.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 22.84b USD (from netDebt column, last quarter)
Enterprise Value = 74.62b USD (66.06b + Debt 30.95b - CCE 22.39b)
Interest Coverage Ratio = 19.70 (Ebit TTM 28.42b / Interest Expense TTM 1.44b)
EV/FCF = 10.93x (Enterprise Value 74.62b / FCF TTM 6.83b)
FCF Yield = 9.15% (FCF TTM 6.83b / Enterprise Value 74.62b)
FCF Margin = 6.38% (FCF TTM 6.83b / Revenue TTM 107.07b)
Net Margin = 5.35% (Net Income TTM 5.73b / Revenue TTM 107.07b)
Gross Margin = 37.59% ((Revenue TTM 107.07b - Cost of Revenue TTM 66.82b) / Revenue TTM)
Gross Margin QoQ = 33.84% (prev 35.69%)
Tobins Q-Ratio = 0.55 (Enterprise Value 74.62b / Total Assets 135.85b)
Interest Expense / Debt = 1.18% (Interest Expense 366.0m / Debt 30.95b)
Taxrate = 21.0% (US default 21%)
NOPAT = 22.45b (EBIT 28.42b * (1 - 21.00%))
Current Ratio = 1.23 (Total Current Assets 41.45b / Total Current Liabilities 33.72b)
Debt / Equity = 0.76 (Debt 30.95b / totalStockholderEquity, last quarter 40.52b)
Debt / EBITDA = 0.57 (Net Debt 22.84b / EBITDA 40.34b)
Debt / FCF = 3.35 (Net Debt 22.84b / FCF TTM 6.83b)
Total Stockholder Equity = 42.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.23% (Net Income 5.73b / Total Assets 135.85b)
RoE = 13.42% (Net Income TTM 5.73b / Total Stockholder Equity 42.65b)
RoCE = 43.36% (EBIT 28.42b / Capital Employed (Equity 42.65b + L.T.Debt 22.90b))
RoIC = 31.84% (NOPAT 22.45b / Invested Capital 70.53b)
WACC = 5.53% (E(66.06b)/V(97.01b) * Re(7.68%) + D(30.95b)/V(97.01b) * Rd(1.18%) * (1-Tc(0.21)))
Discount Rate = 7.68% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -5.77%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈7.72b ; Y1≈5.07b ; Y5≈2.31b
Fair Price DCF = 20.37 (EV 73.69b - Net Debt 22.84b = Equity 50.85b / Shares 2.50b; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -78.71 | EPS CAGR: -16.60% | SUE: 1.14 | # QB: 1
Revenue Correlation: -68.03 | Revenue CAGR: -5.47% | SUE: 0.09 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.66 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=2.58 | Chg30d=-0.186 | Revisions Net=-1 | Growth EPS=+4.6% | Growth Revenue=-6.8%
EPS next Year (2027-12-31): EPS=2.83 | Chg30d=-0.154 | Revisions Net=+0 | Growth EPS=+9.4% | Growth Revenue=-1.6%